The Delta variant of the SARS-CoV-2 virus is causing a surge in COVID-19 cases globally, including in the United States, where there has been a sharp increase in reported cases. The Clinical Director of the GW Vaccine Research Unit, Dr. David Diemer, discusses the Delta Variant and the Fourth Wave of the COVID-19 Pandemic. Take a look at this article to see what Dr. Diemert has to say
Q&A: Vaccine Researcher David Diemert, MD
Latest News
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).